Basic Information


GTO ID GTC1409
Trial ID NCT01517464
Disease Solid Tumor
Altered gene RB94
Therapeutic/Target gene Therapeutic gene
TherapyGene transfer
Treatment SGT-94
PhasePhase1
Recruitment statusCompleted
TitleA Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors
Year2012
CountryUnited States
Company sponsorSynerGene Therapeutics, Inc.
Other ID(s)SGT94-01
Vector information
Vectorplasmid

Clinical Result

Cohort 1
Administration route intravenous infusion
Dosage 0.6, 1.2, 2.4, 3.6 and 4.8 mg, twice weekly for 3 weeks
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph